Gram-negative bacteria: Novelties about beta-lactamases after 15 years!;Les bêta-lactamases chez les bacilles à Gram-négatif: Que de nouveautés en 15 ans!

Antibiotiques

Volumn 7, Issue 4, 2005, Pages 247-259

  Philippon, A ^a   Arlet, G ^b  

^a université Paris Cité   (France)

^b HÔPITAL TENON   (France)

Author keywords

Beta lactamases; Chromosomal; Evolution; Novelties; Plasmid mediated

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AZTREONAM; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; CARBAPENEM; CARBENICILLIN; CEFEPIME; CEFOTAXIME; CEFOTETAN; CEFPIROME; CEFSULODIN; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN; CEPHAMYCIN; CIPROFLOXACIN; CLAVULANIC ACID; CLOXACILLIN; IMIPENEM; MECILLINAM; MEROPENEM; METICILLIN; OXACILLIN; PENICILLIN G; PIPERACILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TICARCILLIN;

BACTERIAL CHROMOSOME; BACTERIAL GENE; DRUG ABUSE; ENZYME INACTIVATION; GENE LOCATION; GENE SEQUENCE; GENETIC VARIABILITY; GRAM NEGATIVE BACTERIUM; INTEGRON; MOLECULAR CLONING; PLASMID; PRESCRIPTION; PROTEIN FUNCTION; REVIEW;

EID: 29544434606     PISSN: 12945501     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1294-5501(05)80458-3     Document Type: Review

References (19)

1. ARLET G, PHILIPPON A. Les nouvelles β-lactamases à l'aube du troisième millénaire. Rev Franç Lab 2003 ; 352 : 41-55.
2. st century: characterization, epidemiology, and detection of this important resistance threat, Clin Microbiol Rev 2001 ; 14 : 933-51.
3. PATERSON DL. Extended-spectrum beta-lactamases: the European experience. Curr Opin Infect Dis 2001 ; 14 : 697-701.
4. RUPP ME, FEY PD. Extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae: considerations for diagnosis, prevention and drug treatment. Drugs 2003 ; 63 : 353-65.
5. BONNET R. Growing group of extended-spectrum beta-lactamases: the CTX-M enzymes. Antimicrob Agents Chemother 2004 ; 48 : 1-14.
6. LIVERMORE DM, WOODFORD N. Carbapenemases: a problem in waiting? Curr Opin Microbiol 2000 ; 3 : 489-95.
7. SIROT D. Extended-spectrum plasmid-mediated beta-lactamases. J Antimicrob Chemother 1995 ; 36 : 19-34.
8. URBAN C, RAHAL J. Mechanisms and detection of carbapenem resistance in Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter baumannii. Rev Med Microbiol 2004 ; 15 : 63-72.
9. POIREL L, NORDMANN P. Acquired carbapenem-hydrolyzing beta-lactamases and their genetic support. Curr Pharm Biotechnol 2002 ; 3 : 117-27.
10. WELDHAGEN GF, POIREL L, NORDMANN P. Ambler class A extended-spectrum beta-lactamases in Pseudomonas aeruginosa: novel developments and clinical impact. Antimicrob Agents Chemother 2003 ; 47 : 2385-92.
11. ZHIYONG Z, XIAOJU L, YANYU G. Metallo-beta-lactamases of non-fermenting gram-negative bacteria. Rev Med Microbiol 2003 ; 14 : 79-93.
12. PHILIPPON A, ARLET G, JACOBY GA. Plasmid-determined AmpC-type beta-lactamases. Antimicrob Agents Chemother 2002 : 46 : 1-11.
13. HANSON ND. AmpC beta-lactamases: what do we need to know for the future? J Antimicrob Chemother 2003 ; 52 : 2-4.
14. NORDMANN P, POIREL L. Emerging carbapenemases in gram-negative aerobes. Clin Microbiol Infect 2002 ; 8 : 321-31.
15. NAAS T, NORDMANN P. OXA-type beta-lactamases. Curr Pharm Des 1999 ; 5 : 865-79.
16. RODRIGUEZ-MARTINEZ JM, PASCUAL A, GARCIA I, MARTINEZ-MARTINEZ L. Detection of the plasmid-mediated quinolone resistance determinant qnr among clinical isolates of Klebsiella pneumoniae producing AmpC-type beta-lactamase. J Antimicrob Chemother. 2003 ; 52 : 703-706.
17. MAMMERI H, VAN DE LOO M, POIREL L, MARTINEZ-MARTINEZ L, NORDMANN P. Emergence of plasmid-mediated quinolone resistance in Escherichia coli in Europe. Antimicrob Agents Chemother 2005 ; 49: 71-76.
18. HELFAND MS, BONOMO RA. Beta-lactamases: a survey of protein diversity. Curr Drug Targets Infect Disord 2003 ; 3 : 9-23.
19. BUSH K. The impact of beta-lactamases on the development of novel antimicrobial agents. Curr Opin Investig Drugs 2002 ; 3 : 1284-90.